NEW YORK (GenomeWeb News) – Horizon Discovery today announced a research collaboration and licensing deal with AstraZeneca to interrogate oncology-relevant genotypes in order to identify and validate new drug targets.

Horizon will query a defined set of genotypes for synthetic lethality and carry out in vitro screening using the company's siRNA platform, as part of the agreement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.